We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-12.44%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.27B
AUM Growth
-$685M
Cap. Flow
+$21.7M
Cap. Flow %
0.66%
Top 10 Hldgs %
61.39%
Holding
65
New
6
Increased
5
Reduced
5
Closed
10

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$77M
2
JANX icon
Janux Therapeutics
JANX
+$69M
3
CRGX
CARGO Therapeutics
CRGX
+$27.9M
4
BCYC
Bicycle Therapeutics
BCYC
+$20.6M
5
ITOS
iTeos Therapeutics
ITOS
+$17.9M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$75M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$65.8M
3
ALEC icon
Alector
ALEC
+$24.4M
4
NKTX icon
Nkarta
NKTX
+$21.6M
5
OVID icon
Ovid Therapeutics
OVID
+$18.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Miscellaneous 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$445M 13.62%
11,607,425
+250,000
+2% +$11.3M
PRTA icon
2
Prothena Corp
PRTA
$479M
$239M 7.31%
11,584,280
– –
SRPT icon
3
Sarepta Therapeutics
SRPT
$2.2B
$222M 6.8%
1,407,322
-512,513
-27% -$65.8M
ANAB icon
4
AnaptysBio
ANAB
$1.67B
$188M 5.77%
7,521,024
– –
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$9B
$186M 5.69%
4,155,375
– –
ARVN icon
6
Arvinas
ARVN
$600M
$179M 5.48%
6,726,491
– –
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$170M 5.19%
4,982,945
+2,598,561
+109% +$77M
LKFT
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$143M 4.36%
5,756,268
– –
KURA icon
9
Kura Oncology
KURA
$1.13B
$120M 3.66%
5,806,871
– –
TNGX icon
10
Tango Therapeutics
TNGX
$3.94B
$114M 3.5%
13,330,736
– –
ZYME icon
11
Zymeworks
ZYME
$2.02B
$114M 3.5%
13,437,473
– –
JAZZ icon
12
Jazz Pharmaceuticals
JAZZ
$15.9B
$108M 3.31%
1,013,952
– –
XNCR icon
13
Xencor
XNCR
$1.94B
$101M 3.09%
5,330,416
– –
CRSP icon
14
CRISPR Therapeutics
CRSP
$5.58B
$75M 2.3%
1,389,276
– –
JANX icon
15
Janux Therapeutics
JANX
$1.1B
$61.6M 1.88%
+1,469,818
New +$69M
NUVB icon
16
Nuvation Bio
NUVB
$2.34B
$56.1M 1.72%
19,209,643
– –
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
$51.6M 1.58%
5,714,404
+95,625
+2% +$907K
ITOS
18
DELISTED
iTeos Therapeutics
ITOS
$48.2M 1.48%
3,249,835
+1,250,586
+63% +$17.9M
IMNM icon
19
Immunome
IMNM
$3.13B
$46.9M 1.44%
3,879,415
– –
NGNE icon
20
Neurogene
NGNE
$732M
$46.3M 1.42%
1,271,342
– –
THRD
21
DELISTED
Third Harmonic Bio
THRD
$41.4M 1.27%
3,182,444
– –
MRSN
22
DELISTED
Mersana Therapeutics
MRSN
$38.9M 1.19%
774,588
– –
VYGR icon
23
Voyager Therapeutics
VYGR
$218M
$31M 0.95%
3,917,546
– –
RNAM
24
DELISTED
Avidity Biosciences
RNAM
$30.9M 0.95%
757,576
– –
TCRX icon
25
TScan Therapeutics
TCRX
$51.1M
$29.3M 0.89%
5,000,000
– –
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2024 Portfolio in Review

As of Q2 2024, EcoR1 Capital held 65 positions worth $3.27B, down 17% from $3.95B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital's Q2 2024 filing shows 6 new, 5 increased, 5 reduced and 10 closed positions. Its largest new stake was Janux Therapeutics: 1,469,818 shares worth $61.6M. The largest sale was Acadia Pharmaceuticals, an estimated $75M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q2 2024 buy was Janux Therapeutics: 1,469,818 shares worth $61.6M.
  • EcoR1 Capital added most to Morphic Holding, Inc. Common Stock in Q2 2024, an estimated $77M increase.
  • EcoR1 Capital's biggest Q2 2024 reduction was Acadia Pharmaceuticals, cutting an estimated $75M.
  • EcoR1 Capital fully exited Alector in Q2 2024, selling an estimated $24.4M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $3.27B portfolio in Q2 2024.
  • EcoR1 Capital opened 6 new positions and closed 10 in Q2 2024.
  • EcoR1 Capital's portfolio value fell 17% quarter-over-quarter to $3.27B.

Based on EcoR1 Capital's 13F filing for Q2 2024, filed 14 Aug 2024.